 |
|
Prevention of Relapse in SchizophreniaAn Evaluation of Fluphenazine Decanoate
Nina R. Schooler, PhD;
Jerome Levine, MD;
Joanne B. Severe, MS;
Benjamin Brauzer, MD;
Alberto DiMascio, PhD;
Gerald L. Klerman, MD;
Vicente B. Tuason, MD
Arch Gen Psychiatry. 1980;37(1):16-24.
Abstract
| |
• We tested the role of guaranteed delivery of medication in the prevention of relapse and the enhancement of adjustment in the community in patients with schizophrenia. Two hundred and ninety newly hospitalized patients at four hospitals were randomly assigned to groups receiving either long-acting injectable fluphenazine decanoate or short-acting oral fluphenazine hydrochloride. After discharge and stabilization, patients were treated in the community for up to one year. By the end of the year, 28% of all the patients had relapsed. Contrary to hypothesis, differences between the two treatment groups in relapse percentages were not significant. Furthermore, there were no differences between the treatment groups as to development of affective symptomatology or social adjustment. Patients who rated themselves as having more symptom distress at the start of the community-maintenance phase of the study relapsed much earlier while receiving fluphenazine decanoate rather than fluphenazine hydrochloride. The results suggest that compliance is not an important determinant of relapse among newly discharged schizophrenic patients.
Author Affiliations
From the Psychopharmacology Research Branch, National Institute of Mental Health, Rockville, Md (Drs Schooler and Levine, Ms Severe), University of Miami, Miami (Dr Brauzer), Boston State Hospital, Boston (Dr DiMascio), Erich Lindemann Mental Health Center, Boston (Dr Klerman), and St Paul-Ramsey Hospital and Medical Center, St Paul (Dr Tuason).
Footnotes
Accepted for publication June 29, 1979.
Read before the Collegium Internationale Neuropsychopharmacologicum, Vienna, July 11, 1978.
Reprint requests to 5600 Fishers Lane, Rockville, MD 20857 (Dr Schooler).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Historical perspective on antipsychotic long-acting injections
Johnson
Br. J. Psychiatry 2009;195:S7-S12.
ABSTRACT
| FULL TEXT
Delusional Infestation
Freudenmann and Lepping
Clin. Microbiol. Rev. 2009;22:690-732.
ABSTRACT
| FULL TEXT
Teaching Medication Compliance to Psychiatric Residents: Placing an Orphan Topic Into a Training Curriculum
Weiden and Rao
Acad. Psychiatry 2005;29:203-210.
ABSTRACT
| FULL TEXT
Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia
Keith et al.
Psychiatr. Serv. 2004;55:997-1005.
ABSTRACT
| FULL TEXT
Is there a role for the depot clinic in the modern management of schizophrenia?
O'Ceallaigh and Fahy
Psychiatr. Bull. 2001;25:481-484.
FULL TEXT
Family Psychoeducation, Social Skills Training, and Maintenance Chemotherapy in the Aftercare Treatment of Schizophrenia: I. One-Year Effects of a Controlled Study on Relapse and Expressed Emotion
Hogarty et al.
Arch Gen Psychiatry 1986;43:633-642.
ABSTRACT
The Rape Victim: Psychological Correlates of Participation in the Legal Process
CLUSS et al.
Criminal Justice and Behavior 1983;10:342-357.
Low-Dose Neuroleptic Treatment of Outpatient Schizophrenics: I. Preliminary Results for Relapse Rates
Kane et al.
Arch Gen Psychiatry 1983;40:893-896.
ABSTRACT
Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics
Mandel et al.
Arch Gen Psychiatry 1982;39:197-203.
ABSTRACT
Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia
Kane et al.
Arch Gen Psychiatry 1982;39:70-73.
ABSTRACT
Psychiatry
Freedman
JAMA 1980;243:2208-2210.
ABSTRACT
|
